Trial Profile
Safety and Efficacy of Prophylactic Defibrotide in Children, Adolescents, and Young Adults With Sickle Cell Disease or Beta Thalassemia Following MAC and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Defibrotide (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- 24 Oct 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 24 Oct 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 02 Aug 2021 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.